Enbrel
Coverage of Enbrel in the Nexus archive.
- Judge suspends Colorado's price cap on prescription drug Embrel while lawsuit plays out
A Colorado judge suspended the state's price cap on the arthritis drug Enbrel, ruling it interferes with federal patent law. The cap, set at $31,000 annually, was blocked ahead of its 2027 implementation. Colorado's Prescription Drug Affordability Board, the first state entity to price-cap a drug, now faces legal uncertainty as Amgen challenges the policy.
- STAT+: Pharmalittle: We’re reading about a court win for Amgen, Novo seeking supplier discounts, and more
A U.S. judge blocked Colorado from capping the price of Amgen's Enbrel, citing potential harm to the company, while a new Medicare program will offer obesity drugs at $50/month. Novo Nordisk and Eli Lilly's weight-loss treatments will be included in the trial.
- A pharmaceutical company is trying to block Colorado’s first-in-the-nation drug price cap in court
A pharmaceutical company is challenging Colorado's first-in-the-nation price cap on a brand-name drug in court. Colorado's Prescription Drug Affordability Board (PDAB) set a cap on the drug Enbrel after determining it was unaffordable, prompting a lawsuit from Amgen. A judge is considering whether to issue a temporary injunction to block the cap while the case proceeds.